Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 8-K (Current Report)
Date of Report: December 23, 2024
Event Date: December 22, 2024
Context: The Company entered into a securities purchase agreement for a registered direct offering and a concurrent private placement of common stock and warrants.
Key Financial Metrics and Transaction Details
| Metric | Value |
|---|---|
| Shares Sold | 709,220 shares of Common Stock |
| Warrants Issued | 709,220 Purchase Warrants (1:1 ratio) |
| Combined Price | $4.935 per Share and Warrant |
| Warrant Exercise Price | $4.81 per share |
| Warrant Expiration | 2 years from issuance |
| Expected Gross Proceeds | Approximately $3.5 million |
| Placement Agent Fees | 7.0% cash fee + 1.0% management fee on gross proceeds |
| Placement Agent Warrants | 49,645 shares (7% of shares sold) at $6.1688 exercise price |
Use of Proceeds: Working capital and general corporate purposes.
Closing Date: Expected December 24, 2024.
Material Changes and Restrictions
- Capital Structure Change: The offering increases the number of outstanding shares and introduces new warrant obligations.
- Lock-up Period: The Company agreed to restrictions on issuing or selling Common Stock or convertible securities for 45 days following the closing.
- Variable Rate Transaction Ban: The Company agreed not to effect any Variable Rate Transaction for one year following the closing, subject to exceptions.
- Registration Obligation: The Company must file a registration statement for the resale of warrant shares within 30 days and seek effectiveness within 90 days.
Outlook, Risks, and Management Commentary
Forward-Looking Statements: The filing contains statements regarding the completion of the offering and the use of proceeds, which are subject to customary closing conditions.
Key Risks Identified:
- Inability to implement revenue, sales, and marketing strategies to increase revenues.
- Patient outcomes may not achieve desired results.
- Regulatory scrutiny and adverse publicity in the sleep apnea treatment sector.
- Risk of inability to secure additional financing on reasonable terms or maintain Nasdaq listing.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting fees and expenses.
- Confirm the effective date of the registration statement for the resale of Purchase Warrant Shares.
- Review the full text of the Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification terms.
- Monitor the Company's cash position and runway given the reliance on working capital for operations.
- Check for any subsequent filings regarding the 45-day lock-up period expiration.